BIOMAT Database Logo BIOMAT Database Logo

Construction and characterization of retroviral vectors for interleukin-2 gene therapy. 1997

H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
Sidney Kimmel Cancer Center, Clemma A. Hewitt Gene Therapy Laboratory, San Diego, California, USA.

Several investigators have employed interleukin-2 (IL-2) gene transfer to enhance the immunogenicity of tumor cell vaccines. We describe in this report the construction and characterization of retroviral vectors for IL-2 gene therapy. Human IL-2 cDNA with a chimeric rat preproinsulin/IL-2 DNA leader sequence was subcloned into the pLXSN (long terminal repeat promoter) and pLNCX (cytomegalovirus [CMV] promoter) vectors to generate the plasmids pLXSN-iIL2 and pLNCX-iIL2, respectively. Human IL-2 cDNA with a chimeric human tissue factor/IL-2 DNA leader sequence was utilized to construct the vector pLXSN-tIL2. The levels of IL-2 secreted by transduced tumor cells and fibroblasts were evaluated by enzyme-linked immunosorbent assay (ELISA) of culture supernatants and compared with those of normal peripheral blood mononuclear cells (PBMC) activated in vitro with calcium ionophore and phorbol 12-myristate 13-acetate. The highest levels of IL-2 secreted by transduced tumor cells (760 units/10(6) cells/24 h), adult fibroblasts (625 units/10(6) cells/24 h), and embryonic fibroblasts (3,975 units/10(6) cells/24 h) were 150- to 1,000-fold higher than than secreted by the activated PBMC (4 units/10(6) cells/24 h). Similar levels of IL-2 were expressed by human fibroblasts transduced with pLXSN vectors employing the preproinsulin (pLXSN-iIL2) or tissue factor (pLXSN-tIL2) leader sequences (range in IL-2 units/10(6) cells/24 h pLXSN-iIL2 = 375-625 vs. pLXSN-tIL2 = 90-440). Because IL-2-transduced cells for clinical applications are generally irradiated to prevent cellular proliferation, we evaluated the effects of radiation on IL-2 production. Radiation doses between 1,500 and 10,000 cGy resulted in gradual decreases in IL-2 secretion by transduced cells. The range of the decrease in IL-2 secretion was 7-11% by day 7, 0-29% by day 14, and 25-50% by day 35. For clinical applications, stable production of the vector in high concentrations is an important consideration. The retroviral vector pLXSN-tIL2 produced the highest viral titer and was chosen for further characterization. Southern blot analysis of SacI-digested genomic DNA from the LXSN-tIL2 producer cell line and SacI-digested pLXSN-tIL2 plasmid DNA revealed the expected 3.2-kbp fragment, suggesting the absence of transgene rearrangement and the suitability of this vector as a candidate for clinical applications.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D011384 Proinsulin A pancreatic polypeptide of about 110 amino acids, depending on the species, that is the precursor of insulin. Proinsulin, produced by the PANCREATIC BETA CELLS, is comprised sequentially of the N-terminal B-chain, the proteolytically removable connecting C-peptide, and the C-terminal A-chain. It also contains three disulfide bonds, two between A-chain and B-chain. After cleavage at two locations, insulin and C-peptide are the secreted products. Intact proinsulin with low bioactivity also is secreted in small amounts.
D011498 Protein Precursors Precursors, Protein
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
Construction and characterization of retroviral vectors expressing biologically active human interleukin-12.
December 1994, Human gene therapy,
H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
Retroviral vectors for gene therapy.
October 2010, Future microbiology,
H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
Retroviral vectors for gene therapy.
June 1998, Indian journal of experimental biology,
H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
Retroviral Vectors for Cancer Gene Therapy.
January 2016, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
Retroviral vectors for suicide gene therapy.
January 2004, Methods in molecular medicine,
H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
Retroviral vectors for cancer gene therapy.
January 2000, Ernst Schering Research Foundation workshop,
H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
Targeting of retroviral vectors for gene therapy.
April 1993, Human gene therapy,
H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
[Gene therapy using retroviral vectors].
December 2003, Uirusu,
H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
Gene therapy using retroviral vectors.
December 1994, Current opinion in biotechnology,
H Fakhrai, and D L Shawler, and C Van Beveren, and H Lin, and O Dorigo, and M J Solomon, and R A Gjerset, and L Smith, and R M Bartholomew, and C A Boggiano, and D P Gold, and R E Sobol
[Retroviral vectors in gene therapy].
January 2000, Voprosy meditsinskoi khimii,
Copied contents to your clipboard!